Dianthus
United States · $400.0M raised
- Business Model
- B2B
- Total Funding
- $400.0M
- Last Round
- $288.0M Venture RoundSep 2023
- Rounds
- 3
About
Clinical-stage biotech developing next-generation complement antibody therapeutics for rare autoimmune diseases.
Summary
Dianthus is a Biotech company based in United States. It has raised $400.0M in total across 3 rounds, most recently a $288.0M Venture Round round in Sep 2023. Investors include 5AM Ventures, Bain Capital Life Sciences and Avidity Partners.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Sep 2023
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...